Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.

J Virol

Division of Hematology/Oncology, Viral Oncology Program, Sylvester Comprehensive Cancer Center, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.

Published: August 2011

miR-155, processed from the B-cell integration cluster (BIC), is one of the few well-studied microRNAs (miRNAs) and is involved in both innate immunity and tumorigenesis. BIC/miR-155 is induced by distinct signaling pathways, but little is known about the underlying mechanisms. We have identified two conserved potential interferon (IFN) regulatory factor (IRF)-binding/interferon-stimulated response element motifs in the Bic gene promoter. Two oncogenic IRFs, IRF4 and -7, in addition to some other members of the family, bind to and significantly transactivate the Bic promoter. Correspondingly, the endogenous levels of IRF4 and -7 are correlated with that of the BIC transcript in Epstein-Barr virus (EBV)-transformed cells. However, RNA interference studies have shown that depletion of IRF4, rather than of IRF7, dramatically decreases the endogenous level of BIC by up to 70% in EBV- or human T-cell leukemia virus type 1 (HTLV1)-transformed cell lines and results in apoptosis and reduction of proliferation rates that are restored by transient expression of miR-155. Moreover, the endogenous levels of the miR-155 target, SHIP1, are consistently elevated in EBV- and HTLV1-transformed cell lines stably expressing shIRF4. In contrast, transient expression of IRF4 decreases the SHIP1 level in EBV-negative B cells. Furthermore, the level of IRF4 mRNA is significantly correlated with that of BIC in adult T-cell lymphoma/leukemia (ATLL) tumors. These results show that IRF4 plays an important role in the regulation of BIC in the context of EBV and HTLV1 infection. Our findings have identified Bic as the first miRNA-encoding gene for IRFs and provide evidence for a novel molecular mechanism underlying the IRF/BIC pathway in viral oncogenesis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147954PMC
http://dx.doi.org/10.1128/JVI.00570-11DOI Listing

Publication Analysis

Top Keywords

bic
9
oncogenic irfs
8
irfs provide
8
human t-cell
8
t-cell leukemia
8
leukemia virus
8
virus type
8
expression mir-155
8
endogenous levels
8
correlated bic
8

Similar Publications

MicroRNAs (miRNAs) have been recognised as potential biomarkers due to their specific expression patterns in different biological tissues and their changes in expression under pathological conditions. MicroRNA-122 (miR-122) is a vertebrate-specific miRNA that is predominantly expressed in the liver and plays an important role in liver metabolism and development. Dysregulation of miR-122 expression is associated with several liver-related diseases, including hepatocellular carcinoma and drug-induced liver injury (DILI).

View Article and Find Full Text PDF

Tissue clearing enables deep imaging of long biological structures using light microscopy approaches. Protocols such as iDISCO are not currently available for human skin. Here, we present Skin-iDISCO, a tissue-clearing and labeling protocol for morphometric analysis of human cutaneous vasculature.

View Article and Find Full Text PDF

Background: Real-world data on treatment patterns and clinical outcomes for newer drugs, including integrase strand transfer inhibitors, among older people with human immunodeficiency virus (PWH) are limited.

Methods: This cohort study included PWH enrolled in the Veterans Aging Cohort Study (VACS) who were prescribed a standard 3-drug antiretroviral therapy (ART) regimen containing dolutegravir (DTG), bictegravir (BIC), cobicistat boosted elvitegravir (EVG), raltegravir (RAL), or darunavir/ritonavir (DRV) plus 2 nucleoside reverse transcriptase inhibitors between January 1, 2014, and March 31, 2020, and who were ≥50 years at regimen initiation. The association between regimen and virologic effectiveness or discontinuation was assessed using logistic regression models with inverse probability of treatment weights.

View Article and Find Full Text PDF

Background: Accurate fasting plasma glucose (FPG) trend prediction is important for management and treatment of patients with type 2 diabetes mellitus (T2DM), a globally prevalent chronic disease. (Generalised) linear mixed-effects (LME) models and machine learning (ML) are commonly used to analyse longitudinal data; however, the former is insufficient for dealing with complex, nonlinear data, whereas with the latter, random effects are ignored. The aim of this study was to develop LME, back propagation neural network (BPNN), and mixed-effects NN models that combine the 2 to predict FPG levels.

View Article and Find Full Text PDF

Brain Metabolic Resilience in Alzheimer's Disease: A Predictor of Cognitive Decline and Conversion to Dementia.

Am J Geriatr Psychiatry

December 2024

Department of Neurology (HL, BHK, EHL, DS, HY, SWS, JPK), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Alzheimer's Disease Convergence Research Center (HL, BHK, EHL, DS, HY, SWS, JPK), Samsung Medical Center, Seoul, Republic of Korea; Neuroscience Center (EHL, DS, SWS, JPK), Samsung Medical Center, Seoul, Republic of Korea. Electronic address:

Objective: Brain atrophy measured by structural imaging has been used to quantify resilience against neurodegeneration in Alzheimer's disease. Considering glucose hypometabolism is another marker of neurodegeneration, we quantified metabolic resilience (MR) based on Fluorodeoxyglucose positron emission tomography (FDG PET) and investigated its clinical implications.

Methods: We quantified the MR and other resilience metrics, including brain resilience (BR) and cognitive resilience (CR), using partial least squares path modeling from the ADNI database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!